Interview with Charles Woler, CEO, Endotis Pharma
Endotis was incorporated in 2003 on the basis of a technology transfer from on a French public research institution. Can you elaborate on the origins? The group was founded from…
Address: 102 avenue Gaston Roussel
93230 Romainville France
Tel: +33 (0)1 48 46 43 91
Endotis Pharma is a biopharmaceutical company dedicated to the discovery and development of small-glyco drugs (SGDs, heparin / heparan sulphate mimetics) for use in thrombosis, oncology and a range of other indications with several potential blockbuster drugs. Founded in february 2003, Endotis is a privately held company which currently employs 34 people between sites in Paris and Lille.
Endotis’ business model is to develop antithrombotic drugs in man until proof-of principle (oral anticoagulants) or Phase IIb dose finding (parenteral antithrombotics), and then partner them; while in other therapeutic areas such as oncology, partnering could take place once proof of concept in animal is demonstrated.
Endotis has three main areas of activity:
– A derisked thrombosis franchise of heparin-derived synthetic oligosaccharides
– An oncology pipeline consisting of heparan sulfate mimetics
– A drug discovery engine: unique know-how from discovery to manufacturing of small-glyco drugs (SGDs) with range of applications
Endotis was incorporated in 2003 on the basis of a technology transfer from on a French public research institution. Can you elaborate on the origins? The group was founded from…
In an exclusive interview, Agnès Buzyn, Chairwoman of the Board for the French National Authority for Health (Haute Autorité de Santé – HAS), on her organization’s priorities, the particularities of…
Shedding light on the unique business model of French pharma’s most successful mid-cap. Not long ago, Laboratories Servier was considered a somewhat mysterious and opaque actor on the world…
Due to high unmet medical need, oncology is set to remain as the number one therapeutic area globally in the coming years. France has traditionally been a leader in this…
AFKLM Cargo’s Director Pharma, Renate de Walle and Sales & Business Developer Manager Pharma France, Fabrice Panza speak about AFKLM Cargo recently achieved IATA Centre of Excellence for Independent Validators…
Lyon’s innovative roots, favourable location, educational excellence, and collaborative culture are all helping to make the city a premium life science, pharmaceuticals and biotech hub, not just in France, but globally. The…
Philippe Choukroun (PC) and Patricia Hatesuer (PH) of AAA speak about the Alsace region in France and the attractiveness of the life science cluster within the tri-national Biovalley area. They…
France provides a unique environment for dermo-cosmetics companies such as Pierre Fabre, Uriage, and Galderma to thrive in terms of the industry’s historical legacy in the country, abundant natural resources, and a…
France has a rich history in innovation, especially in the medical devices sector, but has not been able to produce a giant in the sector to compare with the global impact of…
Orange Healthcare CEO Elie Lobel discusses the importance of digitalization to the healthcare industry, major challenges, and the tremendous work that has already been done in the e-health regulatory field…
Philippe Richert, President of the newly created region Grand Est (Regions Alsace, Champagne-Ardenne and Lorraine) shares the significance of life sciences to his local economy, the industrial heritage which have…
Gilles Pacaud and Christophe Bourillon discuss the importance of life sciences to Rockwell Automation France, industry trends and how the company caters to them, new opportunities in serialization, and being…
As President of Biopharma Activities for Merck in France, Pierre-Henry Longeray reveals how France is the third ranked affiliate after the US and Germany for the Group; how the French…
See our Cookie Privacy Policy Here
